𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A controlled trial of remacemide hydrochloride in Huntington's disease

✍ Scribed by Dr. Karl Kieburtz; Andrew Feigin; Michael McDermott; Peter Como; David Abwender; Carol Zimmerman; Charlyne Hickey; Constance Orme; Kathy Claude; Jennie Sotack; J. Timothy Greenamyre; Cynthia Dunn; Ira Shoulson

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
450 KB
Volume
11
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were randomized to receive either placebo or active remacemide at dosages of 200 mg/day or 600 mg/day. The primary outcome measure was the proportion of subjects able to compleate the study with the assigned treatment. Remacemide was generally well tolerated, and no significant differences between the treatment arms were found in the primary outcome measure. A trend toward impovement in chorea was observed among subjects administered remacemide 200 mg/day. Based on the tolerability and safety demonstrated during this short‐trem trial, remacemide warrants more extended controlled investigation in patients with HD.

📜 SIMILAR VOLUMES

A controlled trial of fluoxetine in nond
A controlled trial of fluoxetine in nondepressed patients with Huntington's disease
✍ Dr. Peter G. Como; Allen J. Rubin; Chris F. O'Brien; Kathy Lawler; Charlyne Hick 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract To examine the antidepressant specificity of fluoxetine in Huntington's disease (HD), we carried out a randomized, double‐blind, placebo‐controlled trial of this medication in nondepressed HD patients. Thirty patients with early HD who were not depressed (Hamilton Depression Inventory <

A controlled trial of piracetam in intel
A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease
✍ Mary Sano; Yaakov Stern; Karen Marder; Richard Mayeux 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 428 KB 👁 1 views

## Abstract Twenty patients with Parkinson's disease and marked intellectual impairment or dementia participated in a double‐blind placebo controlled trial of the nootropic, piracetam. A standardized neurological examination, a neuropsychological test battery, and a functional scale, The Sickness I

A futility study of minocycline in Hunti
A futility study of minocycline in Huntington's disease
✍ Dr. Merit Cudkowicz; The Huntington Study Group DOMINO Investigators 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract This study assessed the futility of proceeding with a Phase 3 clinical trial of minocycline as a disease‐modifying treatment for Huntington's disease (HD). One hundred fourteen research participants with HD were randomized, 87 to minocycline (200 mg/d) and 27 to placebo. The change in T

Treatment of insomnia in Parkinson's dis
Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo
✍ Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Michael Gara; Karina Bi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being co